uniQure Announces Pricing of Upsized $300 Million Public Offering




uniQure Announces Pricing of Upsized $300 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $300 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 947,368 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about September 29, 2025, subject to the satisfaction of customary closing conditions.

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen are acting as bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on September 24, 2025 and a final prospectus supplement and the accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at equitycapitalmarkets@vanlanschotkempen.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. 

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our expectations of market conditions, the satisfaction of customary closing conditions and the timing of the public offering, the gross proceeds we expect to receive and other statements identified by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” and similar words or expressions.

Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering, continued interest in our rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading “Risk Factors” in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February 27, 2025, our Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025 and July 29, 2025, the preliminary prospectus supplement filed with the SEC on September 24, 2025 and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts

Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month




Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month

Following last year’s heavy‑bag installation, this year’s activation features pink boxing gloves, a powerful reminder that early detection and multidisciplinary care help patients go the distance.

ISTANBUL, Sept. 25, 2025 (GLOBE NEWSWIRE) — Breast Cancer Awareness Month, observed every October worldwide, is a global health campaign recognised by the World Health Organization and leading cancer societies. Symbolised by the pink ribbon, the month is dedicated to raising awareness, promoting early detection, and supporting those affected by breast cancer through educational events, public screenings, community campaigns and fundraising initiatives.

Acıbadem Hospitals today announced its in‑hospital Breast Cancer Awareness Month campaign, “Ready for All Rounds,” an activation designed to meet patients and visitors where they are inside the hospital with clear calls to action for regular check‑ups and early diagnosis. Building on last year’s heavy punching‑bag installation, this year’s visual focus is pink boxing gloves arranged in the shape of the breast‑cancer ribbon, deployed across clinical corridors, radiology waiting areas, nurse stations, and digital hospital screens. The poster headline “WE ARE READY FOR ALL ROUNDS” with the educational line “Protect yourself with regular check‑ups, and stay strong against breast cancer with early diagnosis” anchors the creative.

“Breast cancer is one of more than 200 tumor types, yet it carries particular weight as the most common cancer worldwide. Each year, around 2.3 million people — predominantly women — receive this diagnosis,” said Professor Metin Çakmakçı, MD, breast‑cancer specialist at Acıbadem. “What changes the story is early detection and a coordinated, expert team.” (Global incidence reference: IARC.)

A campaign built around action inside the hospital

The in‑hospital program ensures that awareness immediately converts into action. Educational posters and screens guide visitors to on‑site breast imaging; staff remind eligible visitors about screening while clinical teams offer same‑day evaluations where appropriate. The creative theme of boxing gloves invites everyone to “step into the ring” for their health while reinforcing a simple message: book the check‑up now.

From first exam to definitive therapy — a comprehensive pathway under one roof

At the Acıbadem Breast Cancer Clinic, patients receive a detailed physical examination followed by appropriate radiologic evaluation (ultrasound, mammography, and/or MRI). When an abnormality such as a lump, mass, or suspicious calcification is detected, a needle biopsy is performed the same day; pathology results are typically ready within 2–3 days to confirm diagnosis and guide treatment. Treatment plans are individualized and may combine surgery, systemic drug therapy (chemotherapy, immunotherapy, targeted therapy, hormone therapy), and radiotherapy using advanced linear accelerators.

“Every physician who touches breast‑cancer care at Acıbadem — from radiology to surgical oncology, medical oncology, radiation oncology, pathology, plastic and reconstructive surgery, and nuclear medicine, literally works on the same corridor,” Prof. Çakmakçı added. “That proximity accelerates decisions, reduces patient anxiety, and improves outcomes, because our team can confer face‑to‑face in minutes rather than days.”

^{Photo: ACIBADEM INTERNATIONAL (from left to right) Prof. Dr. Bülent Saçak, Prof. Dr. Özge Gümüşay, Assoc. Prof. Özden Buturak, Prof. Dr. Metin Çakmakçı, Prof. Dr. Tarık Zafer Nursal, Dr. Mümtaz Özarar – via FL Comms.}

Preserving appearance and quality of life

Surgery is tailored to each patient. Breast‑conserving surgery is possible for the majority; when a mastectomy is necessary (for example, due to tumor or breast size), immediate reconstruction is performed in the same session, helping patients wake up with their body image preserved. “Our first aim is always to conserve the breast when it is oncologically safe. When we must remove it, we rebuild in the same operation,” said Prof. Çakmakçı.

Around‑the‑clock nurse navigation

Acıbadem’s dedicated breast‑care nurses follow each patient closely through diagnostics, treatment, and survivorship and are accessible 24/7 for urgent questions. This model underlines the hospital’s patient‑centered approach at every step.

Younger patients, real hope

While breast‑cancer incidence increases with age, Prof. Çakmakçı noted that young adults can also be affected. “We have many inspiring stories of patients diagnosed in their 20s or 30s who, after modern treatment, are healthy, start families, and lead full lives. Those stories stay with us.”

Why “Ready for All Rounds” now? The evidence behind the message

• Most common cancer worldwide: Female breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases in 2020, and remains the leading cancer diagnosed in women.
• Early detection matters: Mortality decreases when breast cancer is detected and treated early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs.
• FL PR and Communications +90533 020 25 54 early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs
• Screening guidance: The U.S. Preventive Services Task Force (2024) recommends biennial mammography for women aged 40–74 at average risk (Grade B), underscoring the value of screening in lowering mortality. Screening decisions should always be personalized in consultation with a clinician.
• Outcomes when found early: In the U.S., the 5‑year relative survival for localized breast cancer exceeds 99%, illustrating how earlier detection can change prognosis.

If you are eligible for screening, speak with your clinician and book a mammogram. If you notice a new breast lump, skin change, or nipple discharge, seek medical evaluation promptly. For appointments and information about Acıbadem’s Breast Cancer Clinic, please contact us via the QR codes on hospital posters or through our patient services team.

Usage guidance:

• https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040
• https://www.who.int/news-room/fact-sheets/detail/breast-cancer
• https://www.uspreventiveservicestaskforce.org/uspstf/document/ClinicalSummaryFinal/breast-cancer-screening
• https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

About Acıbadem’s Breast Cancer Clinic

The Acıbadem Breast Cancer Clinic in Istanbul provides end‑to‑end care — from same‑day diagnostic workups to individualized treatment and survivorship support — coordinated by a multidisciplinary team of breast surgeons, medical oncologists, radiologists, radiation oncologists, pathologists, plastic and reconstructive surgeons, and nuclear medicine physicians. With adjacent imaging and biopsy facilities on the same corridor and 24/7 nurse navigation, Acıbadem delivers timely, precise, and compassionate breast‑cancer care.

Media Contact:
FL PR and Communications
+90533 020 25 54

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/087fa5db-c01c-4dfd-aa30-4428051f84f4

https://www.globenewswire.com/NewsRoom/AttachmentNg/bd1fa474-6031-410d-9b43-d5f7388e8a9b

https://www.globenewswire.com/NewsRoom/AttachmentNg/11622abd-b071-4319-b225-3bb11f0c99d1

https://www.globenewswire.com/NewsRoom/AttachmentNg/b714c2d9-8611-4063-8351-11604fa2588e

Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month




Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month

Following last year’s heavy‑bag installation, this year’s activation features pink boxing gloves, a powerful reminder that early detection and multidisciplinary care help patients go the distance.

ISTANBUL, Sept. 25, 2025 (GLOBE NEWSWIRE) — Breast Cancer Awareness Month, observed every October worldwide, is a global health campaign recognised by the World Health Organization and leading cancer societies. Symbolised by the pink ribbon, the month is dedicated to raising awareness, promoting early detection, and supporting those affected by breast cancer through educational events, public screenings, community campaigns and fundraising initiatives.

Acıbadem Hospitals today announced its in‑hospital Breast Cancer Awareness Month campaign, “Ready for All Rounds,” an activation designed to meet patients and visitors where they are inside the hospital with clear calls to action for regular check‑ups and early diagnosis. Building on last year’s heavy punching‑bag installation, this year’s visual focus is pink boxing gloves arranged in the shape of the breast‑cancer ribbon, deployed across clinical corridors, radiology waiting areas, nurse stations, and digital hospital screens. The poster headline “WE ARE READY FOR ALL ROUNDS” with the educational line “Protect yourself with regular check‑ups, and stay strong against breast cancer with early diagnosis” anchors the creative.

“Breast cancer is one of more than 200 tumor types, yet it carries particular weight as the most common cancer worldwide. Each year, around 2.3 million people — predominantly women — receive this diagnosis,” said Professor Metin Çakmakçı, MD, breast‑cancer specialist at Acıbadem. “What changes the story is early detection and a coordinated, expert team.” (Global incidence reference: IARC.)

A campaign built around action inside the hospital

The in‑hospital program ensures that awareness immediately converts into action. Educational posters and screens guide visitors to on‑site breast imaging; staff remind eligible visitors about screening while clinical teams offer same‑day evaluations where appropriate. The creative theme of boxing gloves invites everyone to “step into the ring” for their health while reinforcing a simple message: book the check‑up now.

From first exam to definitive therapy — a comprehensive pathway under one roof

At the Acıbadem Breast Cancer Clinic, patients receive a detailed physical examination followed by appropriate radiologic evaluation (ultrasound, mammography, and/or MRI). When an abnormality such as a lump, mass, or suspicious calcification is detected, a needle biopsy is performed the same day; pathology results are typically ready within 2–3 days to confirm diagnosis and guide treatment. Treatment plans are individualized and may combine surgery, systemic drug therapy (chemotherapy, immunotherapy, targeted therapy, hormone therapy), and radiotherapy using advanced linear accelerators.

“Every physician who touches breast‑cancer care at Acıbadem — from radiology to surgical oncology, medical oncology, radiation oncology, pathology, plastic and reconstructive surgery, and nuclear medicine, literally works on the same corridor,” Prof. Çakmakçı added. “That proximity accelerates decisions, reduces patient anxiety, and improves outcomes, because our team can confer face‑to‑face in minutes rather than days.”

^{Photo: ACIBADEM INTERNATIONAL (from left to right) Prof. Dr. Bülent Saçak, Prof. Dr. Özge Gümüşay, Assoc. Prof. Özden Buturak, Prof. Dr. Metin Çakmakçı, Prof. Dr. Tarık Zafer Nursal, Dr. Mümtaz Özarar – via FL Comms.}

Preserving appearance and quality of life

Surgery is tailored to each patient. Breast‑conserving surgery is possible for the majority; when a mastectomy is necessary (for example, due to tumor or breast size), immediate reconstruction is performed in the same session, helping patients wake up with their body image preserved. “Our first aim is always to conserve the breast when it is oncologically safe. When we must remove it, we rebuild in the same operation,” said Prof. Çakmakçı.

Around‑the‑clock nurse navigation

Acıbadem’s dedicated breast‑care nurses follow each patient closely through diagnostics, treatment, and survivorship and are accessible 24/7 for urgent questions. This model underlines the hospital’s patient‑centered approach at every step.

Younger patients, real hope

While breast‑cancer incidence increases with age, Prof. Çakmakçı noted that young adults can also be affected. “We have many inspiring stories of patients diagnosed in their 20s or 30s who, after modern treatment, are healthy, start families, and lead full lives. Those stories stay with us.”

Why “Ready for All Rounds” now? The evidence behind the message

• Most common cancer worldwide: Female breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases in 2020, and remains the leading cancer diagnosed in women.
• Early detection matters: Mortality decreases when breast cancer is detected and treated early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs.
• FL PR and Communications +90533 020 25 54 early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs
• Screening guidance: The U.S. Preventive Services Task Force (2024) recommends biennial mammography for women aged 40–74 at average risk (Grade B), underscoring the value of screening in lowering mortality. Screening decisions should always be personalized in consultation with a clinician.
• Outcomes when found early: In the U.S., the 5‑year relative survival for localized breast cancer exceeds 99%, illustrating how earlier detection can change prognosis.

If you are eligible for screening, speak with your clinician and book a mammogram. If you notice a new breast lump, skin change, or nipple discharge, seek medical evaluation promptly. For appointments and information about Acıbadem’s Breast Cancer Clinic, please contact us via the QR codes on hospital posters or through our patient services team.

Usage guidance:

• https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040
• https://www.who.int/news-room/fact-sheets/detail/breast-cancer
• https://www.uspreventiveservicestaskforce.org/uspstf/document/ClinicalSummaryFinal/breast-cancer-screening
• https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

About Acıbadem’s Breast Cancer Clinic

The Acıbadem Breast Cancer Clinic in Istanbul provides end‑to‑end care — from same‑day diagnostic workups to individualized treatment and survivorship support — coordinated by a multidisciplinary team of breast surgeons, medical oncologists, radiologists, radiation oncologists, pathologists, plastic and reconstructive surgeons, and nuclear medicine physicians. With adjacent imaging and biopsy facilities on the same corridor and 24/7 nurse navigation, Acıbadem delivers timely, precise, and compassionate breast‑cancer care.

Media Contact:
FL PR and Communications
+90533 020 25 54

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/087fa5db-c01c-4dfd-aa30-4428051f84f4

https://www.globenewswire.com/NewsRoom/AttachmentNg/bd1fa474-6031-410d-9b43-d5f7388e8a9b

https://www.globenewswire.com/NewsRoom/AttachmentNg/11622abd-b071-4319-b225-3bb11f0c99d1

https://www.globenewswire.com/NewsRoom/AttachmentNg/b714c2d9-8611-4063-8351-11604fa2588e

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025




OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position
as of June 30, 2025

Nantes, France, September 25, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

Update on AbbVie Partnership related to ABBV-230

The Company initially expected the initiation of Phase 1 trial of ABBV-230 and the related milestone payment in late 2025. Based on current discussions with its partner, the Company now anticipates a delay in the development timeline.

As the Company has no control over the start of this trial, and in line with the principle of prudence, it has chosen to exclude from its current cash projections the related milestone payment from AbbVie.

Cash Position as of June 30, 2025

As of June 30, 2025, OSE Immunotherapeutics’ cash position totalled €41.6 million, compared to €64.2 million as of December 31, 2024.

The cash position includes cash, cash equivalents and fixed-term deposits classified as current and non-current financial assets. As of June 30, 2025, cash and cash equivalents amounted to €25.4 million while fixed-term deposits classified as current and non-current current-financial assets amounted to €16.2 million.

Based on current assumptions and available financial resources, the Company considers that its operations are funded until the beginning of Q4 2026. This cash runway includes a possible exercise of remaining warrants issued to the benefit of Vester Finance¹ but no longer factors in any upcoming milestone from current partnerships. Should one of the anticipated milestones be received in 2026, the cash runway would be extended to at least Q1 2027, as previously communicated.

To extend its runway beyond 2026, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, equity financing and restructuring of its existing debt in addition to potential milestone payments from current partnerships.

2025 Half-Year Interim Financial Results

Due to the rescheduling of the Company’s Annual General Meeting to September 30, 2025, and to allow shareholders to first approve the 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

ABOUT OSE IMMUNOTHERAPEUTICS  
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Click and follow us on LinkedIn.

Follow us on Linkedln.

Contacts

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements can often be identified by the use of the conditional tense and by verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations as well as other similar terms. Although the management of OSE Immunotherapeutics believes that the forward-looking statements and information are reasonable, OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics within the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read alongside OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on OSE Immunotherapeutics’ website. Other than as required by applicable laws, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

1 Retained assumption is a full exercise of the remaining 880,000 warrants by Vester Finance at an estimated price of €6.00 per share.

Attachment

• 250925_EN_2025 June 30 Cash Position_vF

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025




OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position
as of June 30, 2025

Nantes, France, September 25, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

Update on AbbVie Partnership related to ABBV-230

The Company initially expected the initiation of Phase 1 trial of ABBV-230 and the related milestone payment in late 2025. Based on current discussions with its partner, the Company now anticipates a delay in the development timeline.

As the Company has no control over the start of this trial, and in line with the principle of prudence, it has chosen to exclude from its current cash projections the related milestone payment from AbbVie.

Cash Position as of June 30, 2025

As of June 30, 2025, OSE Immunotherapeutics’ cash position totalled €41.6 million, compared to €64.2 million as of December 31, 2024.

The cash position includes cash, cash equivalents and fixed-term deposits classified as current and non-current financial assets. As of June 30, 2025, cash and cash equivalents amounted to €25.4 million while fixed-term deposits classified as current and non-current current-financial assets amounted to €16.2 million.

Based on current assumptions and available financial resources, the Company considers that its operations are funded until the beginning of Q4 2026. This cash runway includes a possible exercise of remaining warrants issued to the benefit of Vester Finance¹ but no longer factors in any upcoming milestone from current partnerships. Should one of the anticipated milestones be received in 2026, the cash runway would be extended to at least Q1 2027, as previously communicated.

To extend its runway beyond 2026, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, equity financing and restructuring of its existing debt in addition to potential milestone payments from current partnerships.

2025 Half-Year Interim Financial Results

Due to the rescheduling of the Company’s Annual General Meeting to September 30, 2025, and to allow shareholders to first approve the 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

ABOUT OSE IMMUNOTHERAPEUTICS  
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Click and follow us on LinkedIn.

Follow us on Linkedln.

Contacts

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements can often be identified by the use of the conditional tense and by verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations as well as other similar terms. Although the management of OSE Immunotherapeutics believes that the forward-looking statements and information are reasonable, OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics within the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read alongside OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on OSE Immunotherapeutics’ website. Other than as required by applicable laws, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

1 Retained assumption is a full exercise of the remaining 880,000 warrants by Vester Finance at an estimated price of €6.00 per share.

Attachment

• 250925_EN_2025 June 30 Cash Position_vF

Arkansas Psychological Association Announces Fall 2025 Conference on Suicide Prevention and Mental Health




Arkansas Psychological Association Announces Fall 2025 Conference on Suicide Prevention and Mental Health

Little Rock, Arkansas, Sept. 25, 2025 (GLOBE NEWSWIRE) — The Arkansas Psychological Association (ArPA) will host its Fall 2025 Conference, “Turning the Tide: Strengthening Hope, Connection, and Community,” on October 9–10, 2025, in Little Rock, AR. This two-day hybrid event will bring together mental health professionals, students, advocates, and community members to address suicide prevention and expand access to mental health resources across Arkansas and beyond. While focused on Arkansas’s mental health landscape, the conference welcomes attendees from neighboring states and nationwide, particularly those interested in rural mental health challenges and evidence-based suicide prevention strategies.

Arkansas Psychological Association’s Fall 2025 Conference

The conference will feature educational sessions, panel discussions, and research presentations, offering both in-person and virtual participation. Attendees may earn continuing education (CE) credits while engaging in crucial conversations around mental health awareness and advocacy.

Highlights of Day 1 (October 9) include sessions such as:

• Mental Health in Arkansas: A Focus on Suicide (1 CE credit) – Speaker: Austin Porter, D.Ph., M.P.H.
• L.E.T.S. Save Lives (1 CE credit) – Moderator: Aresh Assadi, Ed.D., LPC, Board Member of the AFSP Arkansas Chapter and UALR Faculty; Speaker: Kionti Traylor, Program Manager, AFSP Arkansas Chapter
• From Tragedy to Advocacy: Stories of Suicide Loss & Healing (2 CE credits) – Moderator: Dr. Margaret Rutherford, Clinical Psychologist, Author of Perfectly Hidden Depression, Speaker, Host of The SelfWork Podcast; Panelists: Dr. Leigh Anne Bennett, Psychiatrist, Arkansas Psychiatric Clinic; Chris Thomas, Co-Founder & CEO, The Defensive Line; Martha Thomas, Co-Founder & Chief Education Officer, The Defensive Line

Day 2 Keynote (October 10) features John Sommers-Flanagan, Ph.D., clinical psychologist, professor, and author of nine books including Suicide Assessment and Treatment Planning: A Strengths-Based Approach. His keynote, “Integrating Strengths-Based and Traditional Approaches to Suicide Assessment and Treatment,” will provide practical, collaborative strategies for suicide prevention. Attendees can earn up to 6 CE credits during this in-depth training.

“Conferences like this create opportunities not only for professional learning but also for meaningful dialogue that strengthens mental health care across our state,” said Dr. Tisha Deen, ArPA Past-President.

Registration is now open for professionals, students, and community members. To register or learn more, visit: https://arpapsych.org/arpa-events/fall-conference-2025/

About Arkansas Psychological Association

Arkansas Psychological Association (ArPA) is a nonprofit professional organization established in 1949, dedicated to advancing psychology as both a science and a profession across Arkansas. Representing licensed psychologists and mental health professionals, ArPA promotes access to quality care, professional development, research, and advocacy to improve mental health and well-being for all Arkansans. 

Press inquiries

Arkansas Psychological Association
https://arpapsych.org/
Khiela Holmes, PhD (ArPA Executive Director)
office@arpapsych.org
5016146500
Arkansas Psychological Association PO Box 21220 Little Rock, AR 72221

Arkansas Psychological Association Announces Fall 2025 Conference on Suicide Prevention and Mental Health




Arkansas Psychological Association Announces Fall 2025 Conference on Suicide Prevention and Mental Health

Little Rock, Arkansas, Sept. 25, 2025 (GLOBE NEWSWIRE) — The Arkansas Psychological Association (ArPA) will host its Fall 2025 Conference, “Turning the Tide: Strengthening Hope, Connection, and Community,” on October 9–10, 2025, in Little Rock, AR. This two-day hybrid event will bring together mental health professionals, students, advocates, and community members to address suicide prevention and expand access to mental health resources across Arkansas and beyond. While focused on Arkansas’s mental health landscape, the conference welcomes attendees from neighboring states and nationwide, particularly those interested in rural mental health challenges and evidence-based suicide prevention strategies.

Arkansas Psychological Association’s Fall 2025 Conference

The conference will feature educational sessions, panel discussions, and research presentations, offering both in-person and virtual participation. Attendees may earn continuing education (CE) credits while engaging in crucial conversations around mental health awareness and advocacy.

Highlights of Day 1 (October 9) include sessions such as:

• Mental Health in Arkansas: A Focus on Suicide (1 CE credit) – Speaker: Austin Porter, D.Ph., M.P.H.
• L.E.T.S. Save Lives (1 CE credit) – Moderator: Aresh Assadi, Ed.D., LPC, Board Member of the AFSP Arkansas Chapter and UALR Faculty; Speaker: Kionti Traylor, Program Manager, AFSP Arkansas Chapter
• From Tragedy to Advocacy: Stories of Suicide Loss & Healing (2 CE credits) – Moderator: Dr. Margaret Rutherford, Clinical Psychologist, Author of Perfectly Hidden Depression, Speaker, Host of The SelfWork Podcast; Panelists: Dr. Leigh Anne Bennett, Psychiatrist, Arkansas Psychiatric Clinic; Chris Thomas, Co-Founder & CEO, The Defensive Line; Martha Thomas, Co-Founder & Chief Education Officer, The Defensive Line

Day 2 Keynote (October 10) features John Sommers-Flanagan, Ph.D., clinical psychologist, professor, and author of nine books including Suicide Assessment and Treatment Planning: A Strengths-Based Approach. His keynote, “Integrating Strengths-Based and Traditional Approaches to Suicide Assessment and Treatment,” will provide practical, collaborative strategies for suicide prevention. Attendees can earn up to 6 CE credits during this in-depth training.

“Conferences like this create opportunities not only for professional learning but also for meaningful dialogue that strengthens mental health care across our state,” said Dr. Tisha Deen, ArPA Past-President.

Registration is now open for professionals, students, and community members. To register or learn more, visit: https://arpapsych.org/arpa-events/fall-conference-2025/

About Arkansas Psychological Association

Arkansas Psychological Association (ArPA) is a nonprofit professional organization established in 1949, dedicated to advancing psychology as both a science and a profession across Arkansas. Representing licensed psychologists and mental health professionals, ArPA promotes access to quality care, professional development, research, and advocacy to improve mental health and well-being for all Arkansans. 

Press inquiries

Arkansas Psychological Association
https://arpapsych.org/
Khiela Holmes, PhD (ArPA Executive Director)
office@arpapsych.org
5016146500
Arkansas Psychological Association PO Box 21220 Little Rock, AR 72221

PriceMDs announced that it has entered into a senior secured credit facility of up to $20 million




PriceMDs announced that it has entered into a senior secured credit facility of up to $20 million

CLEARWATER, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) — PriceMDs.com, Inc, an innovative healthcare technology and solutions company that significantly reduces medical costs for self-insured employers and their members, announced that it has entered into a senior secured credit facility of up to $20 million funded by BankUnited. PriceMDs was represented by Greenberg Traurig, LLP in the transaction.

Roth Capital Partners acted as exclusive financial advisor for the offering.

About PriceMDs.com, Inc.

PriceMDs.com provides a healthcare services marketplace platform that connects patients, physicians, surgery centers, and medical imaging facilities to deliver cost-effective medical care. The company’s cloud-based solutions enable consumers and employers to access transparent pricing for surgeries, diagnostic imaging, and other healthcare procedures, while helping providers increase patient volume and optimize revenue. PriceMDs.com’s approach leverages technology to bring efficiency and transparency to healthcare purchasing, ensuring affordability and accessibility for patients and organizations alike. For more information on PriceMDs.com, please visit www.pricemds.com.

About BankUnited NYSE: BKU

BankUnited, a national bank headquartered in Miami Lakes, Florida, with operations in Florida, New York, Dallas, Atlanta, Morristown, New Jersey, and Charlotte, North Carolina. BankUnited provides a full range of consumer and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions, and offers certain commercial lending and deposit products through national platforms. 

BankUnited has established a long-standing record of consistent operating performance, supported by a robust capital foundation and prudent risk management practices. We recognize the importance of trust in banking, and we are firmly committed to upholding financial stability and security, providing our clients with confidence and peace of mind.

Over the past decade, BankUnited has repeatedly been recognized as one of the top performing financial institutions in the country by industry-leading sources. In 2025, we were named as one of America’s Most Trustworthy Companies by Newsweek, a testament to our strength and stability. Year over year, BankUnited has been ranked as the #1 South Florida Community Banks based on assets by South Florida Business Journal. www.bankunited.com

About Roth Capital Partners

Roth Capital Partners, LLC (“ROTH”) is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP, with 49 locations, Our team is recognized by rankings in current Chambers & Partners Guides in jurisdictions and practices around the world, based on thousands of interviews with practicing lawyers and clients. In addition, Greenberg Traurig is proud to have more lawyers listed in The Best Lawyers in America^© than any other law firm, a position we have held since 2008.

PriceMDs Media Contact:

Nick Tsolakakis

727-470-8373

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/da33e5a8-8b93-4533-b864-d4d5ebe6454a

PriceMDs announced that it has entered into a senior secured credit facility of up to $20 million




PriceMDs announced that it has entered into a senior secured credit facility of up to $20 million

CLEARWATER, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) — PriceMDs.com, Inc, an innovative healthcare technology and solutions company that significantly reduces medical costs for self-insured employers and their members, announced that it has entered into a senior secured credit facility of up to $20 million funded by BankUnited. PriceMDs was represented by Greenberg Traurig, LLP in the transaction.

Roth Capital Partners acted as exclusive financial advisor for the offering.

About PriceMDs.com, Inc.

PriceMDs.com provides a healthcare services marketplace platform that connects patients, physicians, surgery centers, and medical imaging facilities to deliver cost-effective medical care. The company’s cloud-based solutions enable consumers and employers to access transparent pricing for surgeries, diagnostic imaging, and other healthcare procedures, while helping providers increase patient volume and optimize revenue. PriceMDs.com’s approach leverages technology to bring efficiency and transparency to healthcare purchasing, ensuring affordability and accessibility for patients and organizations alike. For more information on PriceMDs.com, please visit www.pricemds.com.

About BankUnited NYSE: BKU

BankUnited, a national bank headquartered in Miami Lakes, Florida, with operations in Florida, New York, Dallas, Atlanta, Morristown, New Jersey, and Charlotte, North Carolina. BankUnited provides a full range of consumer and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions, and offers certain commercial lending and deposit products through national platforms. 

BankUnited has established a long-standing record of consistent operating performance, supported by a robust capital foundation and prudent risk management practices. We recognize the importance of trust in banking, and we are firmly committed to upholding financial stability and security, providing our clients with confidence and peace of mind.

Over the past decade, BankUnited has repeatedly been recognized as one of the top performing financial institutions in the country by industry-leading sources. In 2025, we were named as one of America’s Most Trustworthy Companies by Newsweek, a testament to our strength and stability. Year over year, BankUnited has been ranked as the #1 South Florida Community Banks based on assets by South Florida Business Journal. www.bankunited.com

About Roth Capital Partners

Roth Capital Partners, LLC (“ROTH”) is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP, with 49 locations, Our team is recognized by rankings in current Chambers & Partners Guides in jurisdictions and practices around the world, based on thousands of interviews with practicing lawyers and clients. In addition, Greenberg Traurig is proud to have more lawyers listed in The Best Lawyers in America^© than any other law firm, a position we have held since 2008.

PriceMDs Media Contact:

Nick Tsolakakis

727-470-8373

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/da33e5a8-8b93-4533-b864-d4d5ebe6454a

EmblemHealth Commits $2 Million To Combat Food Insecurity in New York City




EmblemHealth Commits $2 Million To Combat Food Insecurity in New York City

EmblemHealth partners with local food charities through its 15 Neighborhood Care centers to battle hunger in the Big Apple

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) — New York City’s food pantries are struggling with dwindling funds while facing an increasing demand for their vital services. In response, EmblemHealth — a dedicated not-for-profit health plan with a strong community mission — has pledged $2 million to support food security in the diverse communities it serves. This substantial financial investment is focused on hunger, which has become a significant barrier to maintaining health or seeking healthcare services.

Food insecurity is now the most acute need for individuals and families visiting EmblemHealth Neighborhood Care centers. “We recognize that New Yorkers are currently facing significant challenges and need help feeding their families,” stated EmblemHealth’s Chief Financial Officer Heather Tamborino. “This investment demonstrates our deep commitment to uplifting the communities we serve and also aims to serve as a rallying call for others to join us in addressing this urgent need.”

Recent reports highlight the profound impact of budget cuts on crucial programs, like the Supplemental Nutrition Assistance Program (SNAP), that were compounded by challenges following the suspension of FEMA’s Emergency Food and Shelter Program in February. With these additional cutbacks, many essential programs are struggling to keep their shelves stocked, leaving countless families at risk of hunger.

Through partnerships with The Campaign Against Hunger, City Harvest, and The New York Common Pantry, EmblemHealth will increase its outreach efforts and strengthen its food security effort. By supporting these food justice organizations, EmblemHealth is actively promoting food security and advocating for equitable availability of nutritious food.

EmblemHealth’s funding will also support a variety of food distribution events in the community. At EmblemHealth Neighborhood Care centers, New Yorkers can receive free food at distribution events alongside additional health resources such as free nutrition, fitness, or stress relief classes and connections to community resources. EmblemHealth’s Community Affairs team will host pop-up food distributions and farmers markets in partnership with community-based organizations and local elected officials throughout New York City.

EmblemHealth hopes to inspire other organizations to create a lasting impact in the fight against food insecurity and ensure that New Yorkers can reliably receive essential nutrition during these challenging times. EmblemHealth remains committed to doing what is necessary to improve health outcomes for the communities it serves.

To find upcoming food distribution events and community pop-up events near you, visit emblemhealth.com/food.

Congressman Dan Goldman (NY-10) said, “With the cost of living at record highs, too many working families in New York are struggling just to put food on the table. EmblemHealth’s $2 million investment will make a real difference for our neighbors across the five boroughs, expanding access to healthy food and strengthening the community organizations on the frontlines of fighting hunger every day.” 

Assemblyman Steven Raga (AD-30) said, “No one should ever have to choose between going hungry or paying rent. Now more than ever, we need to work together and provide resources to families who are struggling to put food on the table. This $2 million investment represents an important step towards ensuring hungry New Yorkers have access to nutritious and fulfilling food. Thank you so much to EmblemHealth for leading this important initiative.”

“It’s heartbreaking that one in four children in New York City don’t always know where their next meal will come from. As a result of the immoral cuts that the federal government has made to SNAP and other vital safety net programs, that number is only going to increase – harming not only our children, but also older adults and vulnerable members of our communities,” said Mayor’s Office of Food Policy Executive Director Kate MacKenzie. “I am grateful to EmblemHealth for their generous commitment to food access in communities that need it most so that families have an easier time putting meals on the table.”

Dr. Melony Samuels, Founder and CEO, The Campaign Against Hunger, said, “EmblemHealth has been a valued partner in showing how access to food strengthens the foundation of resilient communities. Our continued partnership is about reaching more New Yorkers and ensuring that nutritious food isn’t out of reach for those who need it most.”

Jilly Stephens, CEO, City Harvest, said, “With EmblemHealth’s support, City Harvest is strengthening our ability to sustainably source and deliver nutritious food for free to New Yorkers at a time when visits to NYC soup kitchens and pantries are at a record high. This collaboration will make a real difference in the lives of our neighbors experiencing food insecurity.”

Stephen Grimaldi, Executive Director, New York Common Pantry, said, “At New York Common Pantry, we work tirelessly to reduce food insecurity through programs that provide meals and support long-term independence in the communities we serve. EmblemHealth’s support helps us meet urgent needs today while equipping families with the tools and support they need to strengthen their long-term well-being.”

About EmblemHealth

EmblemHealth is one of the nation’s largest not-for-profit health insurers, serving members across New York’s diverse communities with a full range of commercial and government-sponsored health plans for employers, individuals, and families. With a commitment to value-based care, EmblemHealth partners with top hospitals and doctors, including its own AdvantageCare Physicians, to deliver quality, affordable, convenient care. At over a dozen EmblemHealth Neighborhood Care locations, members and nonmembers alike have access to community-based health and wellness guidance and resources. For more information, visit emblemhealth.com.

Contact: EmblemHealth Public Relations Office | Email: press@emblemhealth.com